Brian Goff - 02 Apr 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AGIO
Reported as of: 02 Apr 2026
Net transaction value: -$661,850
SEC form: 4
Accepted by SEC: 06 Apr 2026, 16:04:26 UTC
Prior SEC filing: 03 Mar 2026
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as Attorney in Fact for Brian Goff

Key filing fact

Brian Goff filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 06 Apr 2026.

Key facts

This page summarizes Brian Goff's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Apr 2026, 16:04.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$661,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001546216 Primary reporting owner

Goff Brian

Relationship: Chief Executive Officer, Director
Address: C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE
Signature: /s/ William Cook, as Attorney in Fact for Brian Goff
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Options Exercise

Transaction value
Shares: +25,528
Change %: +16%
Price: $0.000000^*
Shares after: 190,076
Date: 02 Apr 2026
Ownership: Direct

AGIO transaction

Common stock

Sale

Transaction value: $432,903
Shares: -12,472
Change %: -6.6%
Price: $34.71
Shares after: 177,604
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F1

AGIO transaction

Common stock

Options Exercise

Transaction value
Shares: +13,500
Change %: +7.6%
Price: $0.000000^*
Shares after: 191,104
Date: 02 Apr 2026
Ownership: Direct

AGIO transaction

Common stock

Sale

Transaction value: $228,947
Shares: -6,596
Change %: -3.5%
Price: $34.71
Shares after: 184,508
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Performance share units

Options Exercise

Transaction value
Shares: -25,528
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Apr 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 25,528
Exercise price
Footnotes: F3, F4

AGIO transaction Derivative

Performance share units

Options Exercise

Transaction value
Shares: -13,500
Change %: -25%
Price: $0.000000^*
Shares after: 40,500
Date: 02 Apr 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 13,500
Exercise price
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022.

Footnote F2

Footnote F3

Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F4

The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Footnote F5

The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.